December 28, 2011

ATTENTION Investors and Finance Professionals:

If you are reading this you should sign up for ValuEngine's award-winning stock valuation and forecast service at the low price of $19.95/month! NO OBLIGATION, 14 Day FREE TRIAL!

CLICK HERE

Big Pharma
VE Medical Sector Pick Amylin Pharma (AMLN,$AMLN) is Up More than 13%
Amylin Pharmaceuticals (AMLN,$AMLN) is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN injection and BYETTA injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is located in San Diego, California with over one thousand five hundred employees nationwide. Amylin Pharma is a strong performer for our VE Forecast 16 Market Neutral Strategy newsletter. Since our rebalance on the 18th of this month, AMLN is up @13% and leads our long side. Amylin was trading at around $10 in mid-December. Shares are still priced below the consensus price target of @13.32. ValuEngine has issued a STRONG BUY recommendation for AMYLIN PHARMA on Dec. 28, 2011. Based on the information we have gathered and our resulting research, we feel that AMYLIN PHARMA has the probability to OUTPERFORM average market performance for the next year. The company exhibits ATTRACTIVE market valuation and company size.

Based on available data as of Dec. 28, 2011, we believe that AMLN should be trading at $25.37. This makes AMLN 54.76% undervalued. Fair Value indicates what we believe the stock should be trading at today if the stock market were perfectly efficient and everything traded at its true worth. For AMLN, we base this on actual earnings per share (EPS) for the previous four quarters of -$0.70, forecasted EPS for the next four quarters of -$1.43, and correlations to the 30- year Treasury bond yield of 3.04%.
ValuEngine Forecast Target Price*
1-Month 3-Month 6-Month 1-Year 2-Year 3-Year 12.1 13.03 13.4 14.44 14.17 14.89

Expected Return
5.43% 13.49% 16.71% 25.80% 23.45% 29.74%

Valuation & Rankings

Valuation 1-M Forecast Return 12-M Return Sharpe Ratio 5-Y Avg Annual Return Volatility Expected EPS Growth Market Cap (billions) Trailing P/E Ratio Forward P/E Ratio PEG Ratio Price/Sales Market/Book Beta Alpha 54.76% undervalued 5.43% -24.27% -0.35 -22.90% 65.15% -105.90% 1.67 n/a n/a n/a 2.54 5.36 1.55 -0.25 Valuation Rank 1-M Forecast Return Rank Momentum Rank Sharpe Ratio Rank 5-Y Avg Annual Rtn Rank Volatility Rank EPS Growth Rank Size Rank Trailing P/E Rank Forward P/E Ratio Rank PEG Ratio Rank Price/Sales Rank Market/Book Rank Beta Rank Alpha Rank 92 100 35 33 29 33 2 78 17 n/a n/a 28 16 27 36

Click HERE to Download a FREE Sample of Our Best Performing Newsletter

MARKET OVERVIEW
Summary of VE Stock Universe
Stocks Undervalued Stocks Overvalued Stocks Undervalued by 20% Stocks Overvalued by 20% 71.45% 28.55% 37.63% 12.54%

SECTOR OVERVIEW
Sector
Aerospace Auto-Tires-Trucks Basic Materials Business Services Computer and Technology Construction Consumer Discretionary Consumer Staples Finance Industrial Products Medical Multi-Sector Conglomerates Oils-Energy Retail-Wholesale Transportation Utilities

Change
-0.13% -0.57% -0.90% -0.18% -0.22% 0.00% 0.09% -0.16% -0.31% -0.26% -0.10% -0.07% -0.26% -0.17% -0.60% 0.33%

MTD
1.27% -1.64% -5.28% 1.07% 0.54% 1.78% 0.49% 2.72% 1.97% -0.08% 1.02% 0.03% -1.87% 0.80% 0.22% 0.00%

YTD
-1.30% -31.43% -23.48% -7.83% -7.03% -19.48% -10.90% -11.16% -6.50% -10.85% -3.08% -13.14% -16.46% -1.25% -13.42% 3.53%

Valuation
2.02% overvalued 13.99% undervalued 8.43% undervalued 2.89% undervalued 4.26% overvalued 8.63% undervalued 8.13% undervalued 6.78% overvalued 11.44% overvalued 10.67% overvalued 11.26% overvalued 1.17% undervalued 12.34% overvalued 5.38% overvalued 0.10% overvalued 10.55% overvalued

Last 12MReturn
-7.78% -1.52% -24.41% 3.08% -5.52% -20.13% -6.78% -2.54% -6.34% -8.31% 24.06% -9.90% -15.93% 0.96% -17.51% 3.03%

P/E Ratio
15.7 22.31 28.02 28.4 35.18 39.06 22.77 19.25 20.27 23.63 28.53 14.52 35.02 21.99 29.84 24.47